Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents

Clinical Cardiology

Volumn 32, Issue 3, 2009, Pages 164-168

  Dean, Jia ^a   Yujie, Zhou ^a   Yingxin, Zhao ^a   Yuyang, Liu ^a   Yonghe, Guo ^a   Wanjun, Cheng ^a   Zheng, Cao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Clopidogrel; Dual antiplatelet; Sirolimus eluting stent; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BALLOON DILATATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPLANTATION; KIDNEY FAILURE; KIDNEY FUNCTION; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PROGNOSIS; STENT THROMBOSIS;

ASPIRIN; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; SIROLIMUS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 64549105710     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20307     Document Type: Article

References (34)

1. Shuchman M: Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med 2006;355:1949-1952
2. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, et al.: Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168
3. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, HunzikerP, et al.: Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-met al. stents. J Am Coll Cardiol 2006;48:2584-2591
4. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, et al.: Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008
5. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, et al.: Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-met al. stent in a real- world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921-929
6. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW: A pooled analysis of data comparing sirolimus-eluting stents with bare-met al. stents. N Engl J Med 2007;356:989-997
7. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB,et al..:Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813-818
8. Hodgson JM, Stone GW, Michael Lincoff A, Klein L, Walpole H, et al.: Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: A report from the society for cardiovascular angiography and interventions drug-eluting stent task force. Catheter Cardiovasc Interv 2007;69:327-333
9. Serruys PW, Daemen J: Are drug-eluting stents associated with a higher rate of late thrombosis than bare met al. stents? Late stent thrombosis: a nuisance in both bare met al. and drug-eluting stents. Circulation 2007;115:1433-1439
10. Park DW, Park SW, Park KH, Lee BK, Kim YH, et al.: Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-356
11. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293: 2126-2130
12. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, et al.: Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-met al., sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45: 947-953
13. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, et al.: Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006;113:1108-1113
14. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, et al.: Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-1521
15. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, et al.: Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004;109:1930-1932
16. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, et al.: Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-2092
17. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, et al.: Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-2809
18. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, et al..: Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 2006;113:414-419
19. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, et al.: Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-181
20. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, et al.: Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-705
21. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, et al.: Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202
22. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, et al..: Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-2111
23. Park JS, Kim YJ, Hong GR: Thrombosis and acute myocardial infarction as consequencesof very late stent malapposition after implantation of a drug-eluting stent. J Invasive Cardiol 2007;19:E163-E165
24. Klinkhardt U, Graff J, Harder S: Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002;71:176-185
25. Warnholtz A, Ostad MA, Velich N, Trautmann C, Schinzel R, et al.: A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a double-blind, randomized study. Atherosclerosis2007;196:689-695
26. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, et al.: Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 2006;26:1648-1652
27. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, et al.: Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006;55:780-784
28. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, et al.: Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-1061
29. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, et al.: Clinical outcomes and stent thrombosis following off-label use of drug- eluting stents. JAMA 2007;297:2001-2009
30. Rocca HP, Kaiser C, Pfisterer M: Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007;28:719- 725
31. Clappers N, Verheugt FW: Hotline sessions of the 28th European congress of cardiology/World congress of cardiology 2006. Eur Heart J2006;27:2896-2899
32. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, et al.: Long-term outcomes with drug-eluting stents versus bare- met al. stents in Sweden. N Engl J Med 2007;356:1009-1019
33. Shuchman M: Debating the risks of drug-eluting stents. N Eng J Med 2007;356:325-328
34. Zimarino M, Renda G, De Caterina R: Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents. Drugs 2005;65:725-732